Gilead Sciences to Present at Upcoming Investor Conferences

$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $GILD alert in real time by email

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences:

  • Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time
  • Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time
  • Baird Global Healthcare Conference on Tuesday, September 10 at 10:50 AM Eastern Time

The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Get the next $GILD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GILD

DatePrice TargetRatingAnalyst
1/10/2025$87.00 → $113.00Equal-Weight → Overweight
Morgan Stanley
12/10/2024$109.00Buy
BofA Securities
11/15/2024$110.00Outperform
Wolfe Research
11/14/2024$125.00Buy
Citigroup
11/8/2024Buy → Hold
Maxim Group
10/21/2024$74.00 → $96.00Market Perform → Outperform
Leerink Partners
10/17/2024$105.00Outperform
Bernstein
10/7/2024$78.00 → $100.00Equal Weight → Overweight
Wells Fargo
More analyst ratings

$GILD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

    -- Strategic Partnership Strengthens Gilead's Inflammation Research Portfolio with the Addition of LEO Pharma's Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. -- -- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology -- Gilead Sciences, Inc. (NASDAQ:GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma's small molecule oral STAT6 (signal transducer and activator of transcription 6

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Gilead Sciences to Present at Upcoming Investor Conference

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening disease

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakthrough Therapy Designation is based on results from the global Phase 2 TROPiCS-03 study ES-SCLC cohort, which showed encouraging results with Trodelvy as a second-line treatment for ES-SCLC. As recently presented at the IASLC 2024 World Conference on Lung Cancer, Trodelvy demonstrated promising antitumor activity in both platinum-resista

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GILD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GILD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GILD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GILD
SEC Filings

See more

$GILD
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GILD
Leadership Updates

Live Leadership Updates

See more
  • Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

    Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Gilead Appoints Cindy Perettie Executive Vice President of Kite

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GILD
Financials

Live finance-specific insights

See more
  • Gilead Sciences Announces Third Quarter 2024 Financial Results

    Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Gilead Sciences Announces Second Quarter 2024 Financial Results

    Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapa

    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GILD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more